ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) and Novo Nordisk A/S (NYSE:NVO – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.
Analyst Ratings
This is a breakdown of current recommendations and price targets for ANI Pharmaceuticals and Novo Nordisk A/S, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ANI Pharmaceuticals | 0 | 4 | 3 | 0 | 2.43 |
| Novo Nordisk A/S | 5 | 16 | 5 | 0 | 2.00 |
ANI Pharmaceuticals currently has a consensus target price of $100.00, indicating a potential upside of 45.88%. Novo Nordisk A/S has a consensus target price of $59.44, indicating a potential upside of 57.14%. Given Novo Nordisk A/S’s higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than ANI Pharmaceuticals.
Risk and Volatility
Institutional & Insider Ownership
76.0% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares ANI Pharmaceuticals and Novo Nordisk A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ANI Pharmaceuticals | 11.22% | 28.34% | 11.18% |
| Novo Nordisk A/S | 33.99% | 53.52% | 19.49% |
Earnings and Valuation
This table compares ANI Pharmaceuticals and Novo Nordisk A/S”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ANI Pharmaceuticals | $883.37 million | 1.76 | $78.34 million | $5.02 | 13.66 |
| Novo Nordisk A/S | $333.65 billion | 0.51 | $15.51 billion | $3.97 | 9.53 |
Novo Nordisk A/S has higher revenue and earnings than ANI Pharmaceuticals. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Novo Nordisk A/S beats ANI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.
About Novo Nordisk A/S
Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
